SIMBA, NCT05338086 / 2021-003609-24: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis ( Study) |
|
|
| Active, not recruiting | 3 | 528 | Europe, RoW | MB09 (denosumab biosimilar), EU-Prolia, Elemental Calcium, Vitamin D | mAbxience Research S.L. | Postmenopausal Women With Osteoporosis | 12/23 | 06/24 | | |
